Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.

被引：2

作者：

Tamura, Kenji

Hashimoto, Jun

Tsuda, Hitoshi

Yoshida, Masayuki

Yamauchi, Hideko

Aogi, Kenjiro

Shimizu, Satoru

Iwata, Hiroji

Masuda, Norikazu

Yamamoto, Naohito

Inoue, Kenichi

Ohno, Shinji

Kuroi, Katsumasa

Sukigara, Tamie

Fujiwara, Yasuhiro

Andoh, Masashi

机构：

[1] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan

[2] Natl Canc Ctr, Dept Breast, Tokyo, Japan

[3] Natl Canc Ctr, Div Med Oncol, Tokyo, Japan

[4] Natl Def Med Coll, Dept Basic Pathol, Tokorozawa, Saitama 359, Japan

[5] Natl Canc Ctr, Dept Pathol & Labs, Tokyo, Japan

[6] St Lukes Int Hosp, Dept Breast Surg Oncol, Tokyo, Japan

[7] NHO Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan

[8] Kanagawa Canc Ctr, Dept Breast Oncol & Endocrine Surg, Yokohama, Kanagawa, Japan

[9] Aichi Canc Ctr, Dept Breast Oncol, Nagoya, Aichi 464, Japan

[10] NHO Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka, Japan

[11] Chiba Canc Ctr, Chiba 2608717, Japan

[12] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan

[13] Kyushu Natl Canc Ctr, Dept Clin Oncol, Fukuoka, Japan

[14] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[15] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Tokyo, Japan

[16] Natl Canc Ctr, Tokyo, Japan

[17] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.1017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1017

引用

页数：1

共 50 条

[1] Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
Masashi Ando
Hideko Yamauchi
Kenjiro Aogi
Satoru Shimizu
Hiroji Iwata
Norikazu Masuda
Naohito Yamamoto
Kenichi Inoue
Shinji Ohono
Katsumasa Kuroi
Tetsutaro Hamano
Tamie Sukigara
Yasuhiro Fujiwara
Breast Cancer Research and Treatment, 2014, 145 : 401 - 409
[2] Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
Ando, Masashi
Yamauchi, Hideko
Aogi, Kenjiro
Shimizu, Satoru
Iwata, Hiroji
Masuda, Norikazu
Yamamoto, Naohito
Inoue, Kenichi
Ohono, Shinji
Kuroi, Katsumasa
Hamano, Tetsutaro
Sukigara, Tamie
Fujiwara, Yasuhiro
BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (02) : 401 - 409
[3] Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial
Kin, Takanori
Ohtani, Shoichiro
Maeda, Reina
Ueno, Ayako
Fujihara, Miwa
Takamatsu, Yuri
Kajiwara, Yukiko
Ito, Mitsuya
Kawasaki, Kensuke
Abe, Keisuke
Sakata, Yasuhiko
Hiraki, Koichi
WORLD JOURNAL OF ONCOLOGY, 2020, 11 (05) : 197 - 203
[4] A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
Masuda, N.
Higaki, K.
Takano, T.
Matsunami, N.
Morimoto, T.
Ohtani, S.
Mizutani, M.
Miyamoto, T.
Kuroi, K.
Ohno, S.
Morita, S.
Toi, M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 229 - 238
[5] Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
David Aguiar Bujanda
Uriel Bohn Sarmiento
Miguel Ángel Cabrera Suárez
Marta Pavcovich Ruiz
Miguel Ángel Limeres González
José Aguiar Morales
Journal of Cancer Research and Clinical Oncology, 2006, 132 : 332 - 338
[6] Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
Bujanda, DA
Sarmiento, UB
Suárez, MAC
Ruiz, MP
González, MAL
Morales, JA
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (05) : 332 - 338
[7] A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
N. Masuda
K. Higaki
T. Takano
N. Matsunami
T. Morimoto
S. Ohtani
M. Mizutani
T. Miyamoto
K. Kuroi
S. Ohno
S. Morita
M. Toi
Cancer Chemotherapy and Pharmacology, 2014, 74 : 229 - 238
[8] Nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in neoadjuvant chemotherapy for resectable breast cancer: Phase II trial
Kin, T.
Fujihara, M.
Yoshimura, Y.
Kajiwara, Y.
Ito, M.
Ohtani, S.
Taniguchi, K.
Morito, T.
Takada, S.
Ichimura, K.
BREAST, 2017, 32 : S79 - S80
[9] Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.
Matsuda, Naoko
Wang, Xiaoping
Krishnamurthy, Savitri
Alvarez, Ricardo H.
Willey, Jie S.
Lim, Bora
Parker, Charla A.
Babiera, Gildy
Booser, Daniel J.
Murray, James L.
Arun, Banu
Brewster, Abenaa M.
Reuben, James M.
Stauder, Michael Charles
Woodward, Wendy A.
Lucci, Anthony
DeSnyder, Sarah Marie
Tripathy, Debu
Valero, Vicente
Ueno, Naoto T.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] Phase II study of neoadjuvant weekly paclitaxel and carboplatin with lapatinib in HER2+breast cancer.
Wong, Andrea Li Ann
Tan, Sing Huang
Soh, I. Peng Thomas
Tan, Chee Seng
Lim, Yi Wan
Pang, Angela
Ho, Jingshan
Ow, Samuel Guan Wei
Sundar, Raghav
Pang, Mei-Yan
Chan, Ching-Wan
Buhari, Shaik Ahmad
Hartman, Mikael
Iau, Philip
Tang, Anthony
Wong, Nan-Soon
Yap, Yoon Sim
Khoo, Bee-Luan
Thiery, Jean Paul
Lee, Soo-Chin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →